Heterogeneity Assessment

A non-parametric statistical test used to determine if observed variability in effect sizes across studies is greater than what would be expected by random sampling error alone.

• Null Hypothesis: All studies share a common true effect size.
• Calculation: Computed as the weighted sum of squared deviations of individual study estimates from the pooled estimate.
• Limitation: Statistical power is low when the number of studies is small, and it does not quantify the magnitude of heterogeneity.

A descriptive metric that quantifies the percentage of total variation across studies attributable to genuine heterogeneity rather than chance.

• Interpretation Ranges:
  • 0%–25%: Low heterogeneity.
  • 25%–50%: Moderate heterogeneity.
  • >75%: High heterogeneity, suggesting pooling may be inappropriate.
• Advantage: Unlike Cochran's Q, the I² value is independent of the number of studies included in the meta-analysis.

An estimate of the between-study variance in a random-effects meta-analysis model, representing the absolute amount of heterogeneity on the same scale as the effect size.

• Purpose: Directly parameterizes the spread of true effects across sites.
• Common Estimators: DerSimonian-Laird (method of moments) and Restricted Maximum Likelihood (REML).
• Clinical Relevance: A large tau² value indicates substantial variability in treatment effects across different hospital populations or protocols.

A statistical range calculated in a random-effects meta-analysis that predicts the plausible true effect size in a future, individual study setting.

• Utility: Provides a more clinically actionable measure than a simple confidence interval by showing the expected range of effects in a new hospital.
• Interpretation: If the interval crosses the null effect line, the treatment may be harmful in some settings even if the average effect is positive.
• Calculation: Incorporates both the standard error of the mean effect and the estimated tau².

A technique to explore sources of heterogeneity by partitioning studies into categorical groups based on a moderator variable.

• Moderator Examples: Study design (retrospective vs. prospective), patient demographics, or specific clinical protocols.
• Statistical Test: Uses a Q-test for subgroup differences to determine if the moderator significantly explains variability.
• Caution: Observational subgroup analyses are hypothesis-generating, not confirmatory, and are susceptible to ecological bias.

An extension of subgroup analysis that uses continuous covariates to model the relationship between study-level characteristics and the observed effect size.

• Mechanism: Regresses the treatment effect against potential effect modifiers like mean patient age or baseline risk.
• Output: Provides a slope coefficient indicating how the effect changes per unit increase in the covariate.
• Risk: Prone to aggregation bias when inferring patient-level relationships from study-level data.

A statistical test that determines whether the observed variability in effect estimates across different sites is greater than what would be expected by random chance alone. It is the foundational significance test for heterogeneity.

• Null Hypothesis: All studies share a common true effect size.
• Calculation: Computed as the weighted sum of squared deviations of individual study estimates from the pooled estimate.
• Limitation: Statistical power is low when the number of sites is small, and it does not quantify the magnitude of heterogeneity.

A descriptive metric that quantifies the percentage of total variation across study sites that is attributable to genuine heterogeneity rather than random sampling error. It is the most widely reported measure in meta-analyses.

• Interpretation: 0% indicates no observed heterogeneity; 25% is low; 50% is moderate; 75% is high.
• Advantage: Unlike Cochran's Q, it is independent of the number of sites and the scale of measurement.
• Formula: I² = 100% * (Q - df) / Q where Q is Cochran's statistic and df is degrees of freedom.

A graphical display that visually represents the effect size and confidence interval from each participating clinical site alongside the pooled summary effect. It is the primary tool for visually assessing heterogeneity.

• Visual Cues: Non-overlapping confidence intervals suggest significant heterogeneity.
• Components: Each row represents a site with a square (effect size) and horizontal line (confidence interval). The diamond at the bottom represents the pooled meta-analytic result.
• Utility: Allows researchers to quickly identify outlier sites that may be driving heterogeneity.

Two distinct statistical frameworks for pooling data that depend directly on the outcome of the heterogeneity assessment. The choice between them critically impacts the interpretation of federated results.

• Fixed-Effect Model: Assumes a single true effect size underlies all sites. Any observed variance is purely due to sampling error. Used when I² is very low.
• Random-Effects Model: Assumes the true effect size varies between sites according to a normal distribution. Incorporates between-study variance (tau-squared) into the weighting, producing wider, more conservative confidence intervals.

The measure of between-study variance in a random-effects meta-analysis. It quantifies the absolute amount of heterogeneity on the scale of the effect size, representing the variance of the true effect sizes across sites.

• Estimation Methods: Common estimators include the DerSimonian-Laird method, Restricted Maximum Likelihood (REML), and the Paule-Mandel estimator.
• Clinical Relevance: A large tau-squared value indicates substantial variability in treatment effects across different patient populations or clinical protocols.

An extension of meta-analysis that uses regression techniques to investigate whether specific study-level covariates explain the observed heterogeneity. It moves beyond simply detecting heterogeneity to identifying its sources.

• Covariates: Can include site-specific variables like average patient age, disease severity, or specific protocol variations.
• Ecological Fallacy: A key limitation is that relationships observed at the site level may not hold at the individual patient level.
• Application: Used in federated settings to determine if a global model is appropriate or if personalization is required.